UTHR Stock Analysis: United Therapeutics | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 26.542m USD | 12M Return: 80% | US91307C1027 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 231M
EPS Trend: 95.2%
Qual. Beats: 0
Rev. Trend: 95.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
United Therapeutics Corporation (NASDAQ: UTHR) is a Silver Spring, Maryland-based biotechnology company founded in 1996 that develops and commercializes therapies for chronic and life-threatening diseases. Its commercial portfolio is anchored in pulmonary arterial hypertension (PAH), an orphan disease market, with products including Tyvaso DPI and Nebulized Tyvaso (inhaled treprostinil), Remodulin injection, Orenitram tablets, and Adcirca. The company also markets Unituxin for high-risk neuroblastoma and sells the Remunity Pump system for subcutaneous Remodulin delivery.
The company has a late-stage pipeline that includes the RemunityPRO Pump and Ralinepag (an oral selective IP receptor agonist) for PAH, plus an expanded use of Nebulized Tyvaso in idiopathic pulmonary fibrosis. United Therapeutics has also invested in a long-term organ transplantation platform, pursuing development-stage xenografts and regenerative medicine products such as UKidney, UHeart, and miroliver, as well as preclinical lung-transplant technologies like EVLP/CLES.
United Therapeutics has historically supplemented its internal R&D with licensing and collaboration agreements, including partnerships with DEKA Research & Development, MannKind Corporation, and Arena Pharmaceuticals. As a large-cap biotechnology issuer within the Health Care sector, the companys revenue model depends on a concentrated set of specialty therapies protected by regulatory exclusivity, with growth tied to label expansions, new product launches, and the longer-term potential of its xenotransplantation program.
- Tyvaso DPI sales accelerate with PH-ILD label expansion
- Xenotransplantation kidney and heart programs advance clinical timelines
- Active share repurchase program supports earnings per share growth
| Net Income: 1.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 6.62 > 1.0 |
| NWC/Revenue: 91.17% < 20% (prev 107.2%; Δ -16.04% < -1%) |
| CFO/TA 0.30 > 3% & CFO 2.15b > Net Income 1.31b |
| Net Debt (-2.62b) to EBITDA (1.49b): -1.76 < 3 |
| Current Ratio: 5.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.8m) vs 12m ago -5.18% < -2% |
| Gross Margin: 86.14% > 18% (prev 88.98%; Δ -2.84% > 0.5%) |
| Asset Turnover: 41.70% > 50% (prev 38.92%; Δ 2.78% > 0%) |
| Interest Coverage Ratio: 117.0 > 6 (EBIT TTM 1.40b / Interest Expense TTM 12.0m) |
| A: 0.40 (Total Current Assets 3.48b - Total Current Liabilities 607.8m) / Total Assets 7.22b |
| B: 1.27 (Retained Earnings 9.16b / Total Assets 7.22b) |
| C: 0.19 (EBIT TTM 1.40b / Avg Total Assets 7.56b) |
| D: 7.81 (Book Value of Equity 6.40b / Total Liabilities 819.8m) |
| Altman-Z'' = 16.20 = AAA |
| DSRI: 0.80 (Receivables 310.3m/379.3m, Revenue 3.15b/3.08b) |
| GMI: 1.03 (GM 88.98% / 86.14%) |
| AQI: 0.73 (AQ_t 0.25 / AQ_t-1 0.34) |
| SGI: 1.02 (Revenue 3.15b / 3.08b) |
| TATA: -0.12 (NI 1.31b - CFO 2.15b) / TA 7.22b) |
| Beneish M = -3.32 (Cap -4..+1) = AA |
As of August 08, 2026, the stock is trading at USD 538.84 with a total of 973,801 shares traded. Over the past week, the price has changed by +4.08%, over one month by -4.41%, over three months by -5.33% and over the past year by +79.96%.
Current recommended Stop Loss: 516.10 (which is 4.2% or 1.7 ATR below the current price).
United Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy UTHR.
- StrongBuy: 9
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 663.2 | 23.1% |
P/E Trailing = 19.0881
P/E Forward = 18.8324
P/S = 8.1492
P/B = 3.7239
P/EG = 2.2213
Revenue TTM = 3.15b USD
EBIT TTM = 1.40b USD
EBITDA TTM = 1.49b USD
Long Term Debt = unknown (none)
Short Term Debt = 7.30m USD (from shortTermDebt, last fiscal year)
Debt = 37.6m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.62b USD (calculated: Debt 37.6m - CCE 2.66b)
Enterprise Value = 23.9b USD (26.5b + Debt 37.6m - CCE 2.66b)
Interest Coverage Ratio = 117.0 (Ebit TTM 1.40b / Interest Expense TTM 12.0m)
EV/FCF = 16.43x (Enterprise Value 23.9b / FCF TTM 1.46b)
FCF Yield = 6.09% (FCF TTM 1.46b / Enterprise Value 23.9b)
FCF Margin = 46.14% (FCF TTM 1.46b / Revenue TTM 3.15b)
Net Margin = 41.56% (Net Income TTM 1.31b / Revenue TTM 3.15b)
Gross Margin = 86.14% ((Revenue TTM 3.15b - Cost of Revenue TTM 437.2m) / Revenue TTM)
Gross Margin QoQ = 87.30% (prev 82.93%)
Tobins Q-Ratio = 3.31 (Enterprise Value 23.9b / Total Assets 7.22b)
Interest Expense / Debt = 31.91% (Interest Expense 12.0m / Debt 37.6m)
Taxrate = 16.66% (262.1m / 1.57b)
NOPAT = 1.17b (EBIT 1.40b * (1 - 16.66%))
Current Ratio = 5.73 (Total Current Assets 3.48b / Total Current Liabilities 607.8m)
Debt / Equity = 0.01 (Debt 37.6m / totalStockholderEquity, last quarter 6.40b)
Debt / EBITDA = -1.76 (Net Debt -2.62b / EBITDA 1.49b)
Debt / FCF = -1.80 (Net Debt -2.62b / FCF TTM 1.46b)
Total Stockholder Equity = 6.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.33% (Net Income 1.31b / Total Assets 7.22b)
RoE = 20.18% (Net Income TTM 1.31b / Total Stockholder Equity 6.50b)
RoCE = 21.22% (EBIT 1.40b / Capital Employed (Total Assets 7.22b - Current Liab 607.8m))
RoIC = 18.10% (NOPAT 1.17b / Invested Capital 6.46b)
WACC = 8.23% (E(26.5b)/V(26.6b) * Re(8.20%) + D(37.6m)/V(26.6b) * Rd(31.91%) * (1-Tc(0.17)))
Discount Rate = 8.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.24 | Cagr: -3.57%
[DCF] Terminal Value 77.97% ; FCFF base≈1.30b ; Y1≈1.49b ; Y5≈2.20b
[DCF] Fair Price = 716.3 (EV 33.0b - Net Debt -2.62b = Equity 35.7b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.16 | EPS CAGR: 16.33% | SUE: 0.80 | # QB: 0
Revenue Correlation: 95.01 | Revenue CAGR: 14.50% | SUE: -0.73 | # QB: 0
EPS current Quarter (2026-09-30): EPS=7.00 | Chg30d=-1.81% | Revisions=-25% | Analysts=12
EPS current Year (2026-12-31): EPS=26.92 | Chg30d=-1.44% | Revisions=+0% | GrowthEPS=-3.4% | GrowthRev=+1.7%
EPS next Year (2027-12-31): EPS=31.51 | Chg30d=-0.34% | Revisions=-10% | GrowthEPS=+17.1% | GrowthRev=+13.7%
[Analyst] Revisions Ratio: -12% (up=6, down=8)